Clinical research indicates that treatment with mineralocorticoid receptor antagonists (MRAs) can suppress the development of cardiac and kidney injury in patients with diabetes and hypertension but is limited by their ability to induce hyperkalaemia. Here, NR3C2 is linked to hypertensive disorder.